Exploring biomarkers for Major Depressive Disorder
Prospective Biomarkers for Treatment Response in Major Depressive Disorder
This study is trying to find biological signs that can help us understand Major Depressive Disorder better by comparing people with the condition to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 480 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT05585047 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify potential biomarkers for Major Depressive Disorder (MDD) by comparing patients with MDD to healthy controls. It will investigate various biological indicators, cognitive functions, and neuroimaging data to understand the differences among MDD subtypes. The study will also track changes in clinical symptoms and biological markers before and after treatment to provide insights into disease prognosis and treatment response. Long-term follow-up will allow researchers to examine the evolution of these indicators over time.
Who should consider this trial
Good fit: Ideal candidates for this study are outpatients or inpatients aged 18-60 who meet the DSM-5 criteria for Major Depressive Disorder.
Not a fit: Patients with psychotic symptoms or other serious mental health disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and personalized treatment strategies for patients with Major Depressive Disorder.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for depression, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The subject is an outpatient/inpatient (but the subject who participated in the experimental treatment does not need to be hospitalized), and passed M.I.N.I. interview confirmed that the subjects met DSM-5 diagnostic criteria of current or past major depressive disorder. 2. Age 18-60 years old, regardless of gender; 3. Right-handed; 4. Junior high school education or above, capable of completing informed consent and cognitive test; 5. During the follow-up period, the subjects can take antidepressant treatment according to the doctor's advice of outpatient or resident. \- Exclusion Criteria: 1. Patients with psychotic symptoms; 2. M.I.N.I. was diagnosed as schizophrenia, schizophrenic affective disorder, schizophrenia-like disorder, Paranoia or current mental symptoms, post-traumatic stress disorder (currently or within the past year) or dysthymia; 3. with brain organic and serious physical diseases (such as thyroid disease, lupus erythematosus, diabetes, lung, liver and kidney) damage, infection, major trauma, etc.) exclude intracranial implants; 4. Clinically significant sensory disturbance that can't be corrected (for example, hearing impairment makes conversation impossible); 5. Pregnant and lactating women; -
Where this trial is running
Changsha, Hunan
- Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: yan zhan, doctor
- Email: yan.zhang@csu.edu.cn
- Phone: 13807315182
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.